PDCD1 and cancer: Moreover, compared to normal tissues, tumor tissues express PD-L1 at considerably higher levels, which drove interest in inhibiting the PD-L1/PD-1 signaling axis as an appealing strategy for cancer immunotherapy [52,53,54].